Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes

Experimental Diabetes Research

Volumn 2012, Issue , 2012, Pages

  Marfella, Raffaele ^a   Sasso, Ferdinando Carlo ^a   Rizzo, Maria Rosaria ^a   Paolisso, Pasquale ^a   Barbieri, Michelangela ^a   Padovano, Vincenzo ^a   Carbonara, Ornella ^a   Gualdiero, Pasquale ^a   Petronella, Pasquale ^a   Ferraraccio, Franca ^a,b   Petrella, Antonello ^a,b   Canonico, Raffaele ^a   Campitiello, Ferdinando ^a   Della Corte, Angela ^a   Paolisso, Giuseppe ^a   Canonico, Silvestro ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLIMEPIRIDE; INSULIN; METFORMIN; SULFONYLUREA; VASCULOTROPIN; VILDAGLIPTIN; ADAMANTANE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, HUMAN; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; NITRILE; PROTEASOME; PYRROLIDINE DERIVATIVE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FOOT ULCER; GLYCEMIC CONTROL; GRANULATION TISSUE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ULCER HEALING; AGED; ANGIOGENESIS; CAPILLARY; CHRONIC DISEASE; CONTROLLED CLINICAL TRIAL; DIABETIC FOOT; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; ITALY; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; PATHOLOGY; TIME; TREATMENT OUTCOME; VERY ELDERLY; WOUND HEALING;

ADAMANTANE; AGED; AGED, 80 AND OVER; CAPILLARIES; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ITALY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; NITRILES; OXIDATIVE STRESS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRROLIDINES; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84870179238     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2012/892706     Document Type: Article

References (33)

1. Boulton A. J. M., The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes/Metabolism Research and Reviews 2008 24 supplement 1 S3 S6 2-s2.0-43049098631 10.1002/dmrr.833 (Pubitemid 351802764)
2. Boulton A. J., Vileikyte L., Ragnarson-Tennvall G., Apelqvist J., The global burden of diabetic foot disease. The Lancet 2005 366 9498 1719 1724 2-s2.0-27744593541 10.1016/S0140-6736(05)67698-2 (Pubitemid 41587452)
3. Bartus C. L., Margolis D. J., Reducing the incidence of foot ulceration and amputation in diabetes. Current Diabetes Reports 2004 4 6 413 418 2-s2.0-12144284499 (Pubitemid 40104216)
4. Yamaguchi Y., Yoshikawa K., Cutaneous wound healing: an update. Journal of Dermatology 2001 28 10 521 534 2-s2.0-0035196741 (Pubitemid 33111321)
5. Oyibo S. O., Jude E. B., Tarawneh I., Nguyen H. C., Armstrong D. G., Harkless L. B., Boulton A. J. M., The effects of ulcer size and site, patient's age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. Diabetic Medicine 2001 18 2 133 138 2-s2.0-0035083550 10.1046/j.1464-5491.2001.00422.x (Pubitemid 32238959)
6. Rafehi H., El-Osta A., Karagiannis T. C., Genetic and epigenetic events in diabetic wound healing. International Wound Journal 2011 8 1 12 21 2-s2.0-78751692338 10.1111/j.1742-481X.2010.00745.x
7. Macfarlane R. M., Jeffcoate W. J., Factors contributing to presentation of diabetic foot ulcers. Diabetic Medicine 1997 14 10 867 870 10.1002/(SICI)1096-9136(199710)14:10<867::AID-DIA475>3.0.CO;2-L (Pubitemid 27448937)
8. Ruffieux P., Hommel L., Saurat J. H., Long-term assessment of chronic leg ulcer treatment by autologous shin grafts. Dermatology 1997 195 1 77 80 2-s2.0-0030789757 (Pubitemid 27326722)
9. Tandara A. A., Mustoe T. A., Oxygen in wound healing-more than a nutrient. World Journal of Surgery 2004 28 3 294 300 2-s2.0-1642269211 10.1007/s00268-003-7400-2 (Pubitemid 38375532)
10. Knighton D. R., Silver I. A., Hunt T. K., Regulation of wound-healing angiogenesis-effect of oxygen gradients and inspired oxygen concentration. Surgery 1981 90 2 262 270 2-s2.0-0019446580 (Pubitemid 11047238)
11. Botusan I. R., Sunkari V. G., Savu O., Catrina A. I., Grünler J., Lindberg S., Pereira T., Ylä-Herttuala S., Poellinger L., Brismar K., Catrina S. B., Stabilization of HIF-1 α is critical to improve wound healing in diabetic mice. Proceedings of the National Academy of Sciences of the United States of America 2008 105 49 19426 19431 2-s2.0-58049209727 10.1073/pnas.0805230105
12. Semenza G. L., Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. Journal of Clinical Investigation 2000 106 7 809 812 2-s2.0-0033803047
13. Chou E., Suzuma I., Way K. J., Opland D., Clermont A. C., Naruse K., Suzuma K., Bowling N. L., Vlahos C. J., Aiello L. P., King G. L., Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002 105 3 373 379 2-s2.0-0037154304 10.1161/hc0302.102143 (Pubitemid 34106188)
14. Marfella R., Esposito K., Nappo F., Siniscalchi M., Sasso F. C., Portoghese M., Di Marino M. P., Baldi A., Cuzzocrea S., Di Filippo C., Barboso G., Baldi F., Rossi F., D'Amico M., Giugliano D., Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes. Diabetes 2004 53 9 2383 2391 2-s2.0-4344593331 10.2337/diabetes.53.9.2383 (Pubitemid 39145593)
15. Catrina S. B., Okamoto K., Pereira T., Brismar K., Poellinger L., Hyperglycemia regulates hypoxia-inducible factor-1 α protein stability and function. Diabetes 2004 53 12 3226 3232 2-s2.0-9444296528 10.2337/diabetes.53. 12.3226 (Pubitemid 39564499)
16. Shi H., Hypoxia inducible factor 1 as a therapeutic target in ischemic stroke. Current Medicinal Chemistry 2009 16 34 4593 4600 2-s2.0-72449163624 10.2174/092986709789760779
17. Xie-Yun X., Mo Z. H., Chen K., He H. H., Xie Y. H., Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation. Medical Science Monitor 2011 17 2 BR35 BR41 2-s2.0-79551706382
18. Van de Velde S., Hogan M. F., Montminy M., mTOR links incretin signaling to HIF induction in pancreatic beta cells. Proceedings of the National Academy of Sciences of the USA 2011 108 41 16876 16882 10.1073/pnas.1114228108
19. Hinchliffe R. J., Valk G. D., Apelqvist J., Armstrong D. G., Bakker K., Game F. L., Hartemann-Heurtier A., Löndahl M., Price P. E., van Houtum W. H., Jeffcoate W. J., A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes/Metabolism Research and Reviews 2008 24 supplement 1 S119 S144 2-s2.0-44949251001 10.1002/dmrr.825 (Pubitemid 351802785)
20. Grey J. E., Enoch S., Harding K. G., Wound assessment. British Medical Journal 2006 332 7536 285 288 2-s2.0-32544441263 10.1136/bmj.332.7536.285 (Pubitemid 43235343)
21. Pasquali D., Rossi V., Staibano S., De Rosa G., Chieffi P., Prezioso D., Mirone V., Mascolo M., Tramontano D., Bellastella A., Sinisi A. A., The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/ prokineticin 1 and 2 and receptor expression in human prostate: up-regulation of EG-VEGF/prokineticin 1 with malignancy. Endocrinology 2006 147 9 4245 4251 10.1210/en.2006-0614 (Pubitemid 44268375)
22. Marfella R., Sasso F. C., Cacciapuoti F., Portoghese M., Rizzo M. R., Siniscalchi M., Carbonara O., Ferraraccio F., Torella M., Petrella A., Balestrieri M. L., Stiuso P., Nappi G., Paolisso G., Tight glycemic control may increase regenerative potential of myocardium during acute infarction. Journal of Clinical Endocrinology & Metabolism 2012 97 3 933 942 10.1210/jc.2011-2037
23. Stroka D. M., Burkhardt T., Desbaillets I., Wenger R. H., Neil D. A., Bauer C., Gassmann M., Candinas D., HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. The FASEB Journal 2001 15 13 2445 2453 (Pubitemid 33063172)
24. Carmeliet P., Mechanisms of angiogenesis and arteriogenesis. Nature Medicine 2000 6 389 395 10.1038/74651 (Pubitemid 30208155)
25. Jiang B. H., Semenza G. L., Bauer C., Marti H. H., Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. American Journal of Physiology 1996 271 4 C1172 C1180 2-s2.0-0029859510
26. Kong X., Alvarez-Castelao B., Lin Z., Castaño J. G., Caro J., Constitutive/hypoxic degradation of HIF- α proteins by the proteasome is independent of von Hippel Lindau protein ubiquitylation and the transactivation activity of the protein. Journal of Biological Chemistry 2007 282 21 15498 15505 2-s2.0-34447522124 10.1074/jbc.M700704200 (Pubitemid 47093272)
27. Ding Q., Dimayuga E., Keller J. N., Proteasome regulation of oxidative stress in aging and age-related diseases of the CNS. Antioxidants and Redox Signaling 2006 8 1-2 163 172 2-s2.0-33644652951 10.1089/ars.2006.8.163 (Pubitemid 43324543)
28. Ciechanover A., The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology 2006 66 supplement 1 S7 S19 2-s2.0-33644859083 (Pubitemid 43739979)
29. Shringarpure R., Grune T., Mehlhase J., Davies K. J. A., Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. Journal of Biological Chemistry 2003 278 1 311 318 2-s2.0-0037414834 10.1074/jbc.M206279200 (Pubitemid 36043578)
30. Ullrich O., Reinheckel T., Sitte N., Hass R., Grune T., Davies K. J. A., Poly-ADP ribose polymerase activates nuclear proteasome to degrade oxidatively damaged histones. Proceedings of the National Academy of Sciences of the United States of America 1999 96 11 6223 6228 2-s2.0-0033033698 10.1073/pnas.96.11.6223 (Pubitemid 29256647)
31. Bento C. F., Pereira P., Regulation of hypoxia-inducible factor 1 and the loss of the cellular response to hypoxia in diabetes. Diabetologia 2011 54 8 1946 1956 2-s2.0-79960904880 10.1007/s00125-011-2191-8
32. Schurmann C., Linke A., Engelmann-Pilger K., 2012The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. Journal of Pharmacology and Experimental Therapeutics 2012 342 1 71 80 10.1124/jpet.111.191098
33. Bulut K., Meier J. J., Ansorge N., Felderbauer P., Schmitz F., Hoffmann P., Schmidt W. E., Gallwitz B., Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF- β -mediated effect. Regulatory Peptides 2004 121 1-3 137 143 2-s2.0-3142568413 10.1016/j.regpep.2004.04.014 (Pubitemid 38901072)